Clinical Trial Update: M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) [Phase 2]

View source ↗

Summary

Phase 2 trial of M7824 monotherapy in second-line biliary tract cancers (cholangiocarcinoma and gallbladder cancer) has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• M7824 (bintrafusp alfa)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-01-10